Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%

Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering will be randomized to receive either brimonidine 0.1% or brinzolamide 1% three-times daily as adjunctive therapy to latanoprost 0.005%

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glaucoma Eye Diseases Ocular Hypertension

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Atlanta, Georgia, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Glaucoma or ocular hypertension in both eyes
Currently being treated with latanoprost 0.005% QD
IOP greater than or equal to 18mm Hg on latanoprost 0.005%
Best-corrected VA of 20/200 or better in each eye
Visual field within 6 months of study entry

Exclusion criteria

Secondary glaucoma
Active intraocular inflammation or macular edema
Intraocular surgery or laser surgery within the past 3 months

Treatment and study plan

latanoprost 0.005% eye drops and brimonidine 0.1% eye drops

Drug

latanoprost 0.005%, 1 drop nightly for 3 months and brimonidine 0.1% three-times daily for 3 months

Other names: Xalatan®, Alphagan® P

latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops

Drug

latanoprost 0.005% 1 drop nightly for 3 months AND brinzolamide 1.0% 1% three-times daily for 3 months

Other names: Xalatan®, Azopt®

Primary outcomes

IOP

Time frame: Month 3

Secondary outcomes

Tolerability

Time frame: Month 3

Sponsors and collaborators

Lead sponsor

Allergan

Industry

Registry information

Important dates

Study start: 2006
Primary completion: 2007
Study completion: 2007
First posted: Feb 26, 2007
Registry last updated: Jan 2, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed